A sham-controlled randomized trial presented at ASTRO 2025 gave low-dose radiotherapy its first credible positive result and vindicated the dose objection to the earlier negative trials. The ASTRO 2026 presentation attempts something considerably harder: structural and long-term clinical endpoints.
AEWS1221 was the first Children's Oncology Group trial to evaluate SBRT, introduced to make treatment of every metastatic site achievable. Preliminary data suggest it reached a minority of eligible patients. That, rather than the local control rate, is the finding that matters.
A planned interim analysis of 40 patients reported an 86 percent pain response to 4 Gy, with 18 percent requesting reirradiation. Because 4 Gy may be given in a single fraction, the question is not treatment burden but whether half the conventional dose is sufficient.
NRG-GU003 established noninferiority of 62.5 Gy in 25 fractions for patient-reported genitourinary and gastrointestinal symptoms at two years. The five-year analysis addresses the endpoints for which the trial was not designed
After the prospective PAM50 signal in NRG-GU006/BALANCE, SPPORT offers an independent test of whether molecular subtype predicts benefit from short-term androgen deprivation — and potentially pelvic nodal radiotherapy.